CoreValve, Inc. Announces that more than 1,000 High-risk Patients have been Treated with its ReValving(R) System for Percutaneous Aortic Valve Replacement (PAVR)

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that the expanded clinical evaluation of its ReValving® System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace. These procedures can be performed under local anesthesia, without the need for surgical cutdown/repair, and without hemodynamic support or artificially accelerating the heart rate.